After signing up, you'll start to receive regular news updates from us.
Qiagen and CytoPathfinder Combines Technologies in RNAi Screening
Complete the form below to unlock access to ALL audio articles.
Qiagen and CytoPathfinder have announced the formation of a strategic partnership between the two companies to combine their technologies in developing advanced tools for high-throughput RNAi screening.
CytoPathfinder has developed a Transfection Microarray technology (TMA) which allows high-throughput siRNA screening on a microarray chip.
Both companies have agreed to combine product knowledge and technology platforms to develop new-generation tools for high-throughput RNAi screening.
These developments have made high-throughput RNAi accessible to both pharmaceutical companies and academic researchers.
